Leila Haddad, MD
Internal Medicine · Dearborn, MINPI 1205981875
Payments from drug & device makers
Across 106 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$583
- Boehringer Ingelheim$427
- AstraZeneca$363
- GSK$337
- Lilly USA, LLC$301
- Bayer$293
- plus $183 from 10 others
What the payments were for
- Food & beverage$2,46999%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $583 |
| Boehringer Ingelheim | 19 | $427 |
| AstraZeneca | 20 | $363 |
| GSK | 16 | $337 |
| Lilly USA, LLC | 15 | $301 |
| Bayer | 5 | $293 |
| AbbVie | 2 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Novartis | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,487 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 343 | $574,621 |
| JardianceEmpagliflozin | 213 | $283,793 |
| EliquisApixaban | 178 | $208,879 |
| FarxigaDapagliflozin Propanediol | 163 | $161,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $89,582 |
| TrulicityDulaglutide | 32 | $53,202 |
| MounjaroTirzepatide | 45 | $44,959 |
| JanuviaSitagliptin Phosphate | 26 | $32,237 |
| XareltoRivaroxaban | 24 | $28,832 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 80 | $25,738 |
| EntrestoSacubitril/Valsartan | 14 | $19,552 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $18,265 |
| LinzessLinaclotide | 21 | $15,413 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $14,303 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $13,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $583 | $574,621343 claims |
| Boehringer IngelheimJardiance | $427 | $283,793213 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $363 | $182,676214 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta | $337 | $121,565200 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $301 | $98,16177 claims |
| Johnson & JohnsonXarelto, Invokana | $17 | $35,82236 claims |
| NovartisEntresto | $18 | $19,55214 claims |
| AbbVieLinzess | $24 | $15,41321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Dearborn
- Abdulhassan SaadDearborn$11.5M
- Ali HazimehDearborn$1.5M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.